About Ambit Biosciences
Ambit Biosciences is a company based in San Diego (United States) founded in 2000 was acquired by Daiichi Sankyo in September 2014. Ambit Biosciences has raised $162.73 million across 6 funding rounds from investors including Daiichi Sankyo, Orbimed and Gimv. The company has 55 employees as of December 31, 2015. Ambit Biosciences offers products and services including Quizartinib, AC410, CSF1R Program, and CEP-32496. Ambit Biosciences operates in a competitive market with competitors including Moderna, Jazz Pharmaceuticals, BeiGene, Advanced Accelerator Applications and Incyte, among others.
- Headquarter San Diego, United States
- Employees 55 as on 31 Dec, 2015
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Ambit Biosciences Corporation
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$162.73 M (USD)
in 6 rounds
-
Latest Funding Round
$50 M (USD), Series E
Nov 07, 2012
-
Investors
Daiichi Sankyo
& 14 more
-
Employee Count
55
as on Dec 31, 2015
-
Acquired by
Daiichi Sankyo
(Sep 28, 2014)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Ambit Biosciences
Ambit Biosciences offers a comprehensive portfolio of products and services, including Quizartinib, AC410, CSF1R Program, and CEP-32496.
FLT3 inhibitor for treating acute myeloid leukemia in oncology.
JAK2 inhibitor targeting autoimmune and inflammatory conditions.
CSF1R inhibitor for oncology and inflammatory disease applications.
BRAF kinase inhibitor for cancer therapy development.
Funding Insights of Ambit Biosciences
Ambit Biosciences has successfully raised a total of $162.73M across 6 strategic funding rounds. The most recent funding activity was a Series E round of $50 million completed in November 2012. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Ambit Biosciences
Ambit Biosciences has secured backing from 15 investors, including venture fund and institutional investors. Prominent investors backing the company include Daiichi Sankyo, Orbimed and Gimv.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Investments are made by OrbiMed in global healthcare innovations across biopharmaceuticals and related fields.
|
Locked | Locked | Locked | |
|
PE firm investing in the US
|
Locked | Locked | Locked | |
|
Healthcare impact investments are managed by Apposite Capital.
|
Locked | Locked | Locked |
Investor details for Ambit Biosciences
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Ambit Biosciences
Investment portfolio details for Ambit Biosciences
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Ambit Biosciences
Detailed financials for Ambit Biosciences
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Ambit Biosciences Comparisons
Peer comparison for Ambit Biosciences
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Ambit Biosciences
Ambit Biosciences operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, Jazz Pharmaceuticals, BeiGene, Advanced Accelerator Applications and Incyte, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| Locked | Locked | Locked |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| Locked | Locked | Locked |
Targeted and immune-oncology drugs for cancer treatment are developed.
|
|
| Locked | Locked | Locked |
Radiopharmaceuticals for oncology diagnostics and therapies are developed and marketed.
|
|
| Locked | Locked | Locked |
Small molecules are developed for cancer and skin disease treatments.
|
|
| Locked | Locked | Locked |
Cancer therapies are developed using selective pathway inhibitors.
|
Detailed competitors of Ambit Biosciences
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Ambit Biosciences
Complete news archive for Ambit Biosciences
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Ambit Biosciences
Ambit Biosciences was founded in 2000 and raised its 1st funding round 7 years after it was founded.
Ambit Biosciences is headquartered in San Diego, United States. It is registered at San Diego, California, United States.
Ambit Biosciences is a funded company, having raised a total of $162.73M across 6 funding rounds to date.
As of Dec 31, 2015, the latest employee count at Ambit Biosciences is 55.
Ambit Biosciences was founded in 2000 in San Diego, United States, focusing on the biotechnology sector. Kinase inhibitors were developed by the company for treating cancer and immune disorders. The lead product, quizartinib, an FLT3 inhibitor, advanced to phase III clinical trials for acute myeloid leukemia. Operations centered on drug discovery and development until the acquisition by Daiichi Sankyo in 2014.
Ambit Biosciences's top competitors include Moderna, Jazz Pharmaceuticals and Advanced Accelerator Applications.
Ambit Biosciences offers Quizartinib, AC410, CSF1R Program, and CEP-32496.
Ambit Biosciences has 15 investors. Key investors include Daiichi Sankyo, Orbimed, Gimv, Horizon Tech Finance, and Aisling Capital.